Filing Flows › Schrodinger (SDGR) › Guidance & outlook

Schrodinger (SDGR) guidance and outlook

Schrodinger (SDGR) raised its guidance on Nov 4, 2026. Schrodinger's 10-Q filed Nov 4, 2026 makes 35 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 4, 2026

• As customers increase the number of licenses they purchase from us, they will typically be able to run a greater number of simultaneous instances of our products, thereby increasing the number of calculations they will be able to perform in parallel, subject to having enough computational capacity.
• In addition to revenue from our collaborations, we may also derive drug discovery revenue from collaborating on or out-licensing our proprietary drug discovery programs when we believe it will help maximize the clinical and commercial opportunities for the program.
• We are party to an exclusive, worldwide collaboration and license agreement with Bristol Myers Squibb Company, or BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas.
• After mutual agreement on the target(s) of interest, we are responsible for the discovery of development candidates.
• We are eligible to receive up to $482.0 million in total milestone payments for the one remaining neurology target currently subject to the collaboration, of which we have recognized $32.0 million as of September 30, 2026, as well as a tiered percentage royalty on net sales of each product commercialized by BMS ranging from mid-single digits to low-double digits, subject to certain specified reductions.
• In September 2022, we entered into a collaboration with Lilly under which we are responsible for the discovery and optimization of small molecule compounds addressing an immunology target.
• Under the terms of the agreement, we received an upfront payment and we are eligible to receive up to $420.0 million in discovery, development and commercial milestone payments for the target.
• In February 2025, we expanded our research collaboration with Lilly to add an undisclosed target to the collaboration, which was subsequently terminated by Lilly in March 2026 for strategic reasons.
• In November 2024, we entered into a research collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas.
• We expect to release the full commercial version of Bunsen by the end of 2026.
• Under the agreement, we plan to collaborate with BMS scientists on developing novel functionality within Bunsen in conjunction with our computational technologies designed to enable large-scale chemical exploration as well as with RetroSynth, our AI-driven synthesis planning platform.
• In July 2024, we launched an initiative to expand our computational platform to predict toxicity associated with binding to off-target proteins.

Schrodinger's latest quarter

Questions

Did Schrodinger raise or lower its guidance?

Schrodinger (SDGR) raised its guidance on Nov 4, 2026.

What does Schrodinger expect?

As customers increase the number of licenses they purchase from us, they will typically be able to run a greater number of simultaneous instances of our products, thereby increasing the number of calculations they will be able to perform in parallel, subject to having enough computational capacity. In addition to revenue from our collaborations, we may also derive drug discovery revenue from collaborating on or out-licensing our proprietary drug discovery programs when we believe it will help maximize the clinical and commercial opportunities for the program. We are party to an exclusive, worl

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.